Gilead files Form 13F: $2.12B in reported holdings

GILEAD SCIENCES, INC. filed a Form 13F reporting its institutional investment manager holdings.

Rhea-AI Filing Summary

GILEAD SCIENCES, INC. filed a Form 13F reporting its institutional investment manager holdings. The report lists 6 information-table entries with a total reported market value of $2,117,784,504. The filing names Gilead Therapeutics A1 Unlimited Co as an other included manager and is signed by CFO Andrew D. Dickinson on 05-08-2026.

Key Figures

Form 13F Information Table Entry Total: 6 entries Form 13F Information Table Value Total: $2,117,784,504 Number of Other Included Managers: 1 +1 more

4 metrics

Form 13F Information Table Entry Total 6 entries Report summary on cover page

Form 13F Information Table Value Total $2,117,784,504 Aggregate market value (rounded to nearest dollar)

Number of Other Included Managers 1 List of other included managers on summary page

Signature Date 05-08-2026 Signature block by Andrew D. Dickinson

Key Terms

Form 13F, Form 13F Information Table, Other Included Manager

3 terms

Form 13F regulatory

"Form 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported)"

A Form 13F is a quarterly filing that large investment managers must submit to disclose their holdings in publicly traded stocks and certain other securities. It acts like a peek into the portfolios of big investors, helping other market participants see what large players are buying or selling and offering clues about investment trends, crowded trades, and potential market impact.

Form 13F Information Table financial

"Form 13F Information Table Entry Total: 6 | Form 13F Information Table Value Total"

Other Included Manager regulatory

"List of Other Included Managers Provide a numbered list of the name(s)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does GILD's Form 13F show about reported holdings?

It reports 6 holdings with a combined value of $2,117,784,504. The schedule aggregates positions managed by Gilead Sciences as an institutional manager and lists one other included manager, Gilead Therapeutics A1 Unlimited Co.

Who signed the GILD Form 13F and when was it filed?

Andrew D. Dickinson, Executive Vice President and CFO, signed the filing. The signature block shows the place as Foster City, CA and the date as 05-08-2026 on the cover page.

How many other included managers are listed in the GILD 13F filing?

The filing lists 1 other included manager. That manager is named as Gilead Therapeutics A1 Unlimited Co with Form 13F File No. 028-25083 on the provided list.

What is the Form 13F Information Table Value Total for GILD?

The report shows a Form 13F Information Table Value Total of $2,117,784,504. This amount is presented on the summary page rounded to the nearest dollar as the aggregate value of reported holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/08/2026 - 05:00 PM Learn about SEC filing dates

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F COVER PAGE

OMB APPROVAL

OMB Number:			3235-0006
Estimated average burden
hours per response:			23.8

Report for the Calendar Year or Quarter Ended: 03-31-2026

Check here if Amendment		Amendment Number:
This Amendment (Check only one.):		is a restatement.
		adds new holdings entries.

Institutional Investment Manager Filing this Report:
Name:	GILEAD SCIENCES, INC.
Address:	333 LAKESIDE DR
	FOSTER CITY, CA 94404
Form 13F File Number:	028-25078
CRD Number (if applicable):
SEC File Number (if applicable):

The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Person Signing this Report on Behalf of Reporting Manager:
Name:		Andrew D. Dickinson
Title:		Executive Vice President and Chief Financial Officer
Phone:		650-574-3000
Signature, Place, and Date of Signing:
/s/ Andrew D. Dickinson			FOSTER CITY, CA	05-08-2026
[Signature]			[City, State]	[Date]

Report Type (Check only one.):
X	13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.)
	13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).)
	13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).)

Form 13F Summary Page
	Report Summary:
	Number of Other Included Managers:		1
	Form 13F Information Table Entry Total:		6
	Form 13F Information Table Value Total:		2,117,784,504
			(round to nearest dollar)

List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
[If there are no entries in this list, state "NONE" and omit the column headings and list entries.]
	No.	Name	Form 13F File No.	CRD No. (if applicable)	SEC File No. (if applicable)	CIK
	1	Gilead Therapeutics A1 Unlimited Co	028-25083			0002055207